Watertown, United States
Lyndra Therapeutics is a biopharmaceutical startup based in the United States, founded in 2015, with a compelling slogan "What if we stopped trying to change the patient and changed the pill instead?" The company has developed the LYNX™ drug delivery platform, aiming to reinvent medicine by offering long-acting oral therapies. With the vision of making a significant impact on global health challenges, Lyndra is focused on therapies for various disorders, including central nervous system (CNS) disorders, opioid use disorder, malaria eradication, and contraception.
The startup has gained momentum with its Series E investment, securing a substantial $101.00M from notable investors including Polaris Partners, Sarissa Capital, and Sun Pharmaceutical Industries on 21 December 2023. This significant financial backing indicates the investors' confidence in Lyndra's potential for growth and innovation in the pharmaceutical industry.
Collaborations with renowned organizations such as the Bill & Melinda Gates Foundation, NIH, AbbVie, and Gilead Sciences, Inc., further substantiate Lyndra's credibility and influence in the healthcare sector. The company's commitment to reinventing medicine for a healthier world is aptly supported by its core values of valuing every voice, resilience, and collaborative contribution to delivering impactful solutions.
Overall, Lyndra Therapeutics' groundbreaking approach to drug delivery and its strategic focus on addressing critical global health issues position it as an exciting prospect for investors seeking to support innovative and transformative ventures in the biotechnology and pharmaceutical industries.
